NRXP 1W Reprieve47% Breakout Play NRXP traveling the measured move of the wedge. Previous break in macro wave (A) falling wedge probably has most investors disinterested. Not me.
−0.5108USD
−39.754MUSD
56.084M
About NRX Pharmaceuticals, Inc.
Sector
CEO
Stephen H. Willard
Headquarters
Wilmington
Website
Founded
2017
ISIN
US6294441000
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
NRXP all time low! 2 X Phase 3 clinical trials! NRx Pharmaceuticals, Inc. (NRXP) has two Phase III assets for which it has Fast Track and Breakthrough Therapy designation, respectively: intravenous ZYESAMI® for Critical COVID-19 and NRX-101 for bipolar depression with suicidality.
52 Week Range 2.38 - 48.80.
in 2020 the stock was $77.
My price
NRX Pharma USASun Storm Investment Trading Desk & NexGen Wealth Management Service Present's: SSITD & NexGen Portfolio of the Week Series
Focus: Worldwide
By Sun Storm Investment Research & NexGen Wealth Management Service
A Profit & Solutions Strategy & Research
Trading | Investment | Stocks | ETF | Mutua
#NRXP 12-22-66
NRX Pharmaceuticals (NRXP) said Friday data from a mid-stage trial showed that the BriLife COVID19 vaccine may be able to protect against the delta variant of SARS-CoV-2, the virus that causes COVID-19.
In the phase 2 study, 10 out of the 11 samples taken from participants to be tested for antibo
NRXP COVID-19 Vaccine Effectiveness Against Delta VariantNRx Pharmaceuticals announced that its BriLife COVID-19 Vaccine is Effectiveness Against Delta Variant.
Information was released by Israel Institute for Biological Research.
Since the pandemic isn`t over, there is a place in the market for new developers that have effective vaccines.
I consider th
NRXP might do some good if it holds support. This is just an idea i will be keeping up with in the future. Here we have a falling wedge with weekly and daily class A bullish divergence. Break out would possibly take us to 22 dollars. This is the .618 retracement from the top of the wedge.
NRXP 15min Scalpers editiontest
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered i
#NRXP Huge Gain May Reach $64 Sector: Health Technology
Industry: Pharmaceuticals: Major
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company
NRXP 1D - Swing PositionNRXP 1D - Swing Position - Not reco to buy/sell
Extreme volatility has been seen consistently in the bio-sectors as seen the chart in the above analysis - NXRP has received consistently positive news regarding their primary drug ZYESAMI and the clinical trials they are actively participating in.
$NRXP entry PT 14.50-14.75 PT 60 and higher...timeline 09/14/202NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
